CD5KO-CART

CD5KO-CART is an investigational autologous CAR-T cell therapy in which the CD5 gene is knocked out (KO) from T-cells using CRISPR-Cas9 or similar gene-editing technology prior to engineering them with a chimeric antigen receptor (CAR) targeting CD5. This strategy aims to treat relapsed or refractory T-cell malignancies, particularly T-cell lymphomas, by improving the expansion, persistence, and cytotoxicity of CAR-T cells relative to conventional anti-CD5 CAR-T approaches. CD5, a surface protein found on T-cells, acts as an immune checkpoint and can restrict T-cell activation; its genetic deletion has been shown in preclinical studies to dramatically enhance CAR-T antitumor activity in both hematological and solid tumor models. Mechanistically, CD5KO-CART cells exhibit heightened activation of the JAK-STAT, MAPK, and mTOR signaling pathways, resulting in greater proliferation, cytotoxicity, and persistence after infusion. Early clinical development is ongoing to assess safety, feasibility, and efficacy for relapsed/refractory T-cell lymphomas[5][6][7][8].

Other names

CD5 knockout CAR-TCD-5 knockout CAR-TCD 5 knockout CAR-TCD5-deleted CAR-TCD-5-deleted CAR-TCD 5-deleted CAR-TCD5KO CAR-TCD-5KO CAR-TCD 5KO CAR-T